The nation’s largest listed hospital chains by market capitalisation, Apollo Hospitals (Apollo) and Max Healthcare (Max), outperformed expectations for the June quarter. Whereas Max Healthcare’s revenues rebounded after two quarters of sluggish development, Apollo maintained an upward year-on-year (Y-o-Y) gross sales trajectory for its hospitals enterprise for the fourth quarter in a row.
Working efficiency of each hospital chains was higher than estimates, although Apollo’s working metrics stood out. Going forward, whereas the demerger of the pharmacy enterprise will unlock worth for Apollo Hospitals, rising occupancies and working efficiencies might enhance the prospects of Max Healthcare. On the returns entrance, Apollo is the clear chief, with features of about 10 per cent over the previous yr, whereas Max has struggled with a 17.5 per cent drop. The Nifty50 is flat over this era.
Powered by the hospitals section, Apollo posted consolidated gross sales development of 21 per cent Y-o-Y. The hospitals section noticed development of twenty-two per cent, with established hospitals, in operation for 5 years, rising 18 per cent. The hospital section’s efficiency was led by 11 per cent quantity development in acute therapies, 4 per cent development in pricing, and a 3 per cent uptick in case and payor combine. Insurance coverage and self-pay accounted for a lot of the revenues and grew 25 per cent and 16 per cent, respectively, over the year-ago interval.
Total occupancy noticed an enchancment of 500 foundation factors Y-o-Y in comparison with 65 per cent within the year-ago quarter. Common income per affected person (ARPP) elevated 8 per cent Y-o-Y to simply below ₹186,600 and was on account of a greater scientific case combine. The corporate expects rising scientific complexity to stay an vital driver of development in ARPPs. Common size of keep additionally improved from 3.09 to three.14 days Y-o-Y. HealthCo, which homes pharmacy and digital operations/Apollo 24/7, noticed income development of 20 per cent Y-o-Y.
Apollo expects total hospital income development of 18-20 per cent throughout FY27, with established hospitals sustaining 13-14 per cent development over the subsequent two years, whereas new hospitals are anticipated to contribute 7 per cent incremental income. New-hospital losses could briefly enhance by ₹20 crore per quarter, with the brand new hospital cluster anticipated to strategy total break-even by Q3-This autumn of FY28.
Max delivered 15.3 per cent income development in Q1 FY27, led by larger volumes and higher realisation. The features got here from larger volumes at current hospitals and 630 mattress additions over the previous yr. The income development was wholesome and got here regardless of the impression of oncology medication, following regulatory adjustments associated to high-value most cancers medication.
Occupancy has remained sturdy at 75 per cent regardless of a 13 per cent Y-o-Y addition in beds over the previous 12 months. Whereas occupancies have remained sturdy, the hospital chain is including beds by acquisitions, brownfield and greenfield growth. The continued growth is predicted to spice up its mattress capability by 2,800 beds over the subsequent two years, elevating its mattress capability by half of the present stage. These additions would entail a capital expenditure outlay of ₹6,100 crore.
The working efficiency of the 2 well being care majors was wholesome, with Apollo having the sting. Apollo’s working revenue margin expanded by 92 foundation factors Y-o-Y to fifteen.5 per cent, pushed by decrease digital money losses at ₹9.7 crore, in opposition to ₹48.7 crore in Q1 FY26. Its established hospitals delivered a 25.9 per cent margin, whereas new hospitals reported a ₹38 crore loss on the working stage throughout the preliminary ramp-up part.
Max reported 15 per cent Y-o-Y development in working revenue and a 2.9 per cent enhance quarter-on-quarter (Q-o-Q). Margins remained flat Y-o-Y and contracted 206 foundation factors Q-o-Q to 24.6 per cent attributable to brownfield capability growth and the Kalinga Hospital acquisition.
Analysts are constructive on each corporations. On Apollo, JM Monetary Analysis believes that when it comes to development, each key companies, hospital and pharmacy, would maintain 18-20 per cent development for the yr. Additional, the pharmacy demerger is predicted to conclude by This autumn FY27, which, in response to analysts led by Amey Chalke of the brokerage, will unlock worth. The brokerage has maintained a purchase score with a goal value of ₹10,446.
For Max, Alternative Institutional Equities says that rising occupancy and common income per working mattress (ARPOB) at newer amenities are projected to progressively unlock working leverage and working revenue development. The Kalinga turnaround, potential medical schooling with 25 per cent return on capital employed (ROCE), and scaling up of Max@House and Max Lab additional help the corporate’s development, level out Deepika Murarka and Stuti Bagadia of the brokerage. They anticipate 24-27 per cent development in revenues and revenue over the subsequent three years and have an add score with a goal value of ₹1,160.